Mulmit

KYNTRA BIO, INC.KYNTRA BIO, INC.

KYNB Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-316,440,000-45,895,000183,452,00045.37
2024-12-3129,621,000-150,416,000-47,579,000-11.89
2023-12-3146,803,000-322,721,000-284,232,000-2.92
2022-12-31140,734,000-301,025,000-293,654,000-3.14
2021-12-31235,309,000-288,530,000-290,023,000-3.14

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-09-06DeLucia DavidChief Financial Officer22
2026-09-06Wettig ThaneCEO209
2026-06-12Ho Maykin7,000
2026-06-12Schoeneck James A7,000
2026-06-12Kauffman Michael7,000
2026-06-12EDWARDS JEFFREY L7,000
2026-06-06DeLucia DavidChief Financial Officer52
2026-06-06Wettig ThaneCEO198
2026-05-14Wettig ThaneCEO2,800
2026-03-06DeLucia DavidChief Financial Officer60
2026-03-06Wettig ThaneCEO277
2026-02-03DeLucia DavidChief Financial Officer26,000

8-K events

FiledItems
2026-08-31Entry into a material agreement · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits
2026-08-13Results of operations · Financial statements and exhibits
2026-06-16Submission of matters to a vote
2026-06-09Other events
2026-05-11Results of operations · Financial statements and exhibits
2026-04-09Delisting or listing-standard notice
2026-03-16Results of operations · Financial statements and exhibits
2026-01-07Amendments to charter or bylaws · Other events · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Pharmaceutical Preparations — 같은 업종, 그리고 규모가 비슷한 기업Pharmaceutical Preparations — and other companies of a similar size

SEC가 같은 업종(Pharmaceutical Preparations)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Pharmaceutical Preparations) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.